Similarly, Park et al. (2019) proposed Lactobacillus amylovorus KU4 as a potential obesity therapeutic by modulating PPAR-γ signaling, while Long et al. (2020) highlighted Lactobacillus KFY04′s ability to mitigate oxidative damage and inflammation through the PPAR pathway. Here, PPARG is linked to obesity disorder.